The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Open accessAbstract
Chromosomal rearrangements have a central role in the pathogenesis of human cancers and often result in the expression of therapeutically actionable gene fusions. A recently discovered example is a fusion between the genes echinoderm microtubule-associated protein like 4 (EML4) and anaplastic lymphoma kinase (ALK), generated by an inversion on the short arm of chromosome 2: inv(2)(p21p23). The EML4-ALK oncogene is detected in a subset of human non-small cell lung cancers (NSCLC) and is clinically relevant because it confers sensitivity to ALK inhibitors. Despite their importance, modelling such genetic events in mice has proven challenging and requires complex manipulation of the germ line. Here we describe an efficient method to induce specific chromosomal rearrangements in vivo using viral-mediated delivery of the CRISPR/Cas9 system to somatic cells of adult animals. We apply it to generate a mouse model of Eml4-Alk-driven lung cancer. The resulting tumours invariably harbour the Eml4-Alk inversion, express the Eml4-Alk fusion gene, display histopathological and molecular features typical of ALK(+) human NSCLCs, and respond to treatment with ALK inhibitors. The general strategy described here substantially expands our ability to model human cancers in mice and potentially in other organisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these events occur at low frequency, they could be significant in a clinical setting if rare translocations led to cancer 97-99 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [98]
Experimental — accuracy not yet measuredIn the citing paper
“In addition, CRISPR/Cas9 system has shown potentials in polygenetic diseases, such as cancer, by inhibiting oncogene expression or deactivating oncogenic virus [52–55].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [55]
In the citing paper
“To establish disease models, in 2014, Maddalo et al. generated a model of non-small cell lung cancer by creating an Eml4 and Alk fusion gene through the intratracheal instillation of AdV-delivered CRISPR/Cas9 [35].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,471
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,428
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,927
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2291 · Cited by 896
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M. J. P., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 873
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 633
Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells
Hindriksen, S., Bramer, A. J., Truong, M. A., Vromans, M. J. M., Post, J. B., Verlaan-Klink, I., Snippert, H. J. G., Lens, S. M. A., & Hadders, M. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179514 · Cited by 46
ALK in cancer: from function to therapeutic targeting
Voena, C., Ambrogio, C., Iannelli, F., & Chiarle, R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00797-9 · Cited by 49
Amin, A. D., Rajan, S. S., Liang, W. S., Pongtornpipat, P., Groysman, M. J., Tapia, E. O., Peters, T. L., Cuyugan, L., Adkins, J. R., Rimsza, L. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3437 · Cited by 48
AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway
Liang, S., Walkey, C. J., Martinez, A. E., Su, Q., Dickinson, M. E., Wang, D., Lagor, W. R., Heaney, J. D., Gao, G., & Xue, W. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.023 · Cited by 44
Feng, W., Dai, Y., Mou, L., Cooper, D. K. C., Shi, D., & Cai, Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036545 · Cited by 44
CRISPR/Cas9-mediated correction of human genetic disease
Men, K., Duan, X., He, Z., Yang, Y., Yao, S., & Wei, Y. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9032-4 · Cited by 44
Zhang, R., He, Z., Shi, Y., Sun, X., Chen, X., Wang, G., Zhang, Y., Gao, P., Wu, Y. X., Lu, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.056 · Cited by 46
Mouse Models of Tumor Immunotherapy
Ngiow, S. F., Loi, S., Thomas, D. M., & Smyth, M. J. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.004 · Cited by 44
Using CRISPR/Cas to study gene function and model disease in vivo
Tschaharganeh, D. F., Lowe, S. W., Garippa, R. J., & Livshits, G. (2016) · FEBS Journal · doi:10.1111/febs.13750 · Cited by 47
Self-citationSong, M. (2017) · Biotechnology Progress · doi:10.1002/btpr.2484 · Cited by 46
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
Afolabi, L. O., Afolabi, M. O., Sani, M. M., Okunowo, W. O., Yan, D., Chen, L., Zhang, Y., & Wan, X. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1286 · Cited by 46
Porcine Models of Pancreatic Cancer
Bailey, K. L., & Carlson, M. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00144 · Cited by 43
Universal toxin-based selection for precise genome engineering in human cells
Li, S., Akrap, N., Cerboni, S., Porritt, M. J., Wimberger, S., Lundin, A., Möller, C., Firth, M. A., Gordon, E., Lazovic, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20810-z · Cited by 46
Paving the way towards precise and safe CRISPR genome editing
Śledziński, P., Dabrowska, M., Nowaczyk, M., & Olejniczak, M. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107737 · Cited by 43
García‐Tuñón, I., Hernández‐Sánchez, M., Ordóñez, J. L., Alonso-Pérez, V., Quijada‐Álamo, M., Benito, R., Guerrero, C., Hernández‐Rivas, J. M., & Sánchez‐Martín, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15215 · Cited by 41
CRISPR/Cas9 for overcoming drug resistance in solid tumors
Saber, A., Liu, B., Ebrahimi, P., & Haisma, H. J. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00240-z · Cited by 45
Islam, M. T., Rumpf, F., Tsuno, Y., Kodani, S., Sakurai, T., Matsui, A., Maejima, T., & Mieda, M. (2022) · Current Biology · doi:10.1016/j.cub.2022.07.020 · Cited by 40
Tang, S., Xue, Y., Qin, Z., Fang, Z., Sun, Y., Yuan, C., Pan, Y., Zhao, Y., Tong, X., Zhang, J., et al. (2023) · National Science Review · doi:10.1093/nsr/nwad028 · Cited by 40
Self-citationShen, H. M., McHale, C. M., Smith, M. T., & Zhang, L. (2015) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2015.01.002 · Cited by 40
CRISPR‐Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies
Wen, W., Yuan, Z., Ma, S., Jiang, X., & Yuan, D. (2015) · International Journal of Cancer · doi:10.1002/ijc.29626 · Cited by 41
CRISPR-Cas9: from Genome Editing to Cancer Research
Chen, S., Sun, H., Miao, K., & Deng, C. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.17421 · Cited by 40
CRISPR/Cas9 editing of the genome for cancer modeling
Guernet, A. A., & Grumolato, L. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.007 · Cited by 44
Lu, H., Villafañe, N., Dogruluk, T., Grzeskowiak, C. L., Kong, K., Tsang, Y. H., Zagorodna, O., Pantazi, A., Yang, L., Neill, N. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2745 · Cited by 42
Review of applications of CRISPR-Cas9 gene-editing technology in cancer research
Zhao, Z., Li, C., Tong, F., Deng, J., Huang, G., & Sang, Y. (2021) · Biological Procedures Online · doi:10.1186/s12575-021-00151-x · Cited by 42
Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
Xiang, Y., Zhang, S., Fang, X., Jiang, Y., Fang, T., Liu, J., & Lu, K. (2022) · Current Oncology · doi:10.3390/curroncol29100618 · Cited by 41
Naranjo, S., Cabana, C. M., LaFave, L. M., Romero, R., Shanahan, S.-L., Bhutkar, A. J., Westcott, P. M. K., Schenkel, J. M., Ghosh, A., Liao, L. Z., et al. (2022) · Genes & Development · doi:10.1101/gad.349659.122 · Cited by 42
CRISPR‐Cas: From the Bacterial Adaptive Immune System to a Versatile Tool for Genome Engineering
Kirchner, M., & Schneider, S. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504741 · Cited by 39
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
Valencia, K., Erice, O., Kostyrko, K., Hausmann, S., Guruceaga, E., Tathireddy, A., Flores, N. M., Sayles, L. C., Lee, A. G., Fragoso, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129012 · Cited by 39
Nano-vectors for CRISPR/Cas9-mediated genome editing
Yang, P., Lee, A. Y.-T., Xue, J., Chou, S., Lee, C., Tseng, P., Zhang, T. X., Zhu, Y., Lee, J., Chiou, S., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101482 · Cited by 41
Applications of Cas9 as an RNA‐programmed RNA‐binding protein
Nelles, D. A., Fang, M. Y., Aigner, S., & Yeo, G. W.-M. (2015) · BioEssays · doi:10.1002/bies.201500001 · Cited by 38
Rutkowski, T. P., Schroeder, J. P., Gafford, G. M., Warren, S. T., Weinshenker, D., Caspary, T., & Mullé, J. G. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23970 · Cited by 40
Katayama, R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.015 · Cited by 38
CRISPR-Cas9 effectors facilitate generation of single-sex litters and sex-specific phenotypes
Douglas, C., Maciulyte, V., Zohren, J., Snell, D. M., Mahadevaiah, S. K., Ojarikre, O. A., Ellis, P. J. I., & Turner, J. M. A. (2021) · Nature Communications · doi:10.1038/s41467-021-27227-2 · Cited by 38
Unlocking Genome Editing: Advances and Obstacles in CRISPR/Cas Delivery Technologies
Kaupbayeva, B., Tsoy, A., Safarova, Y., Nurmagambetova, A., Murata, H., Matyjaszewski, K. A., & Askarova, S. (2024) · Journal of Functional Biomaterials · doi:10.3390/jfb15110324 · Cited by 40
Applications of CRISPR-Cas9 mediated genome engineering
Yang, X. P. (2015) · Military Medical Research · doi:10.1186/s40779-015-0038-1 · Cited by 38
On the expression of recombinant Cas9 protein in E. coli BL21(DE3) and BL21(DE3) Rosetta strains
Carmignotto, G. P., & Azzoni, A. R. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.09.012 · Cited by 38
Xu, W., Yang, Y., Liu, Y., Kang, G., Wang, F., Li, L., Lv, X., Zhao, S., Yuan, S., Song, J., et al. (2019) · Molecular Plant · doi:10.1016/j.molp.2019.10.007 · Cited by 37
Club cells employ regeneration mechanisms during lung tumorigenesis
Chen, Y., Tóth, R., Chocarro, S., Weichenhan, D., Hey, J., Lutsik, P., Sawall, S., Stathopoulos, G. T., Plass, C., & Sotillo, R. (2022) · Nature Communications · doi:10.1038/s41467-022-32052-2 · Cited by 36
Translatable gene therapy for lung cancer using Crispr CAS9—an exploratory review
Nair, J., Nair, A., Veerappan, S., & Sen, D. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0116-8 · Cited by 36
Stimuli-responsive nanomaterials for the precision delivery of mRNA cancer vaccines
Srivastava, R. (2025) · Nano Trends · doi:10.1016/j.nwnano.2025.100147 · Cited by 36
High-Throughput Silencing Using the CRISPR-Cas9 System: A Review of the Benefits and Challenges
Wade, M. R. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115587916 · Cited by 39
Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma
Liu, T., Shen, J. K., Li, Z., Choy, E., Hornicek, F. J., & Duan, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.030 · Cited by 30
Tutorial: design and execution of CRISPR in vivo screens
Braun, C. J., Adames, A. C., Saur, D., & Rad, R. (2022) · Nature Protocols · doi:10.1038/s41596-022-00700-y · Cited by 38
Progresses, Challenges, and Prospects of CRISPR/Cas9 Gene-Editing in Glioma Studies
Kang, X., Wang, Y., Liu, P., Huang, B., Zhou, B., Lu, S., Geng, W., & Tang, H. (2023) · Cancers · doi:10.3390/cancers15020396 · Cited by 37
CRISPR-Cas9: A Revolutionary Tool for Cancer Modelling
Torres-Ruiz, R., & Rodríguez, S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922151 · Cited by 37
CRISPR ‐Cas9 technology and its application in haematological disorders
Zhang, H., & McCarty, N. (2016) · British Journal of Haematology · doi:10.1111/bjh.14297 · Cited by 37
Functional interrogation of non-coding DNA through CRISPR genome editing
Canver, M. C., Bauer, D. E., & Orkin, S. H. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.008 · Cited by 36
Ye, M., Zhang, X., Li, N., Zhang, Y., Jing, P., Chang, N., Wu, J., Ren, X., & Zhang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.6935 · Cited by 35
Engineering CRISPR mouse models of cancer
Weber, J., & Rad, R. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.04.001 · Cited by 33
Gesuita, L., Cavaccini, A., Argunşah, A. Ö., Favuzzi, E., Ibrahim, L. A., Stachniak, T. J., Gennaro, M. D., Utz, S. G., Greter, M., & Karayannis, T. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111209 · Cited by 34
Harnessing the evolving CRISPR/Cas9 for precision oncology
Li, T., Li, S., Kang, Y., Zhou, J., & Yi, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05570-4 · Cited by 35
Richard, G. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.02.003 · Cited by 32
Hu, Z., Zhou, M., Wu, Y. C., Li, Z., Liu, X., Wu, L., & Liang, D. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.05.019 · Cited by 32
Engineering new balancer chromosomes in C. elegans via CRISPR/Cas9
Iwata, S., Yoshina, S., Suehiro, Y., Hori, S., & Mitani, S. (2016) · Scientific Reports · doi:10.1038/srep33840 · Cited by 31
Modeling blood diseases with human induced pluripotent stem cells
Georgomanoli, M., & Papapetrou, E. P. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.039321 · Cited by 35
Phosphorylation Control of p53 DNA-Binding Cooperativity Balances Tumorigenesis and Aging
Timofeev, O. N., Koch, L., Niederau, C., Tscherne, A., Schneikert, J., Klimovich, M., Elmshäuser, S., Zeitlinger, M. A., Mernberger, M., Nist, A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2002 · Cited by 31
Efficient correction of Duchenne muscular dystrophy mutations by SpCas9 and dual gRNAs
Xiang, X., Zhao, X., Pan, X., Dong, Z., Yu, J., Li, S., Liang, X., Han, P., Qu, K., Jensen, J., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.03.005 · Cited by 33
Genetically engineered mouse models for studying radiation biology
Castle, K. D., Chen, M., Wisdom, A. J., & Kirsch, D. G. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.06.19 · Cited by 32
Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches
Sankar, K. N., Nagrath, S., & Ramnath, N. (2021) · Cancers · doi:10.3390/cancers13061476 · Cited by 31
The clear cell sarcoma functional genomic landscape
Panza, E., Ozenberger, B. B., Straessler, K. M., Barrott, J. J., Li, L., Wang, Y., Xie, M., Boulet, A. M., Titen, S. W. A., Mason, C. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146301 · Cited by 30
Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies
Paschoudi, K., Yannaki, E., & Psatha, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119527 · Cited by 30
Kleczko, E. K., & Heasley, L. E. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0816-y · Cited by 31
The EML4-ALK oncogene: targeting an essential growth driver in human cancer
Mano, H. (2015) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.91.193 · Cited by 29
Advancements in CRISPR/Cas9 technology—Focusing on cancer therapeutics and beyond
Mirza, Z., & Karim, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.026 · Cited by 29
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
Qin, Z., Yue, M., Tang, S., Wu, F., Sun, H., Li, Y., Zhang, Y., Izumi, H., Huang, H., Wang, W., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20232028 · Cited by 29
Self-citationProtacs in cancer therapy: mechanisms, design, clinical trials, and future directions
Vikal, A., Maurya, R., Patel, B. B., Sharma, R. K., Patel, P., Patil, U. K., & Kurmi, B. D. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01754-z · Cited by 29
Naert, T., Nieuwenhuysen, T. V., & Vleminckx, K. (2017) · genesis · doi:10.1002/dvg.23005 · Cited by 28
Role of MYC in B Cell Lymphomagenesis
Korać, P., Dotlić, S., Matulić, M., Petranović, M. Z., & Dominis, M. (2017) · Genes · doi:10.3390/genes8040115 · Cited by 30
Application of CRISPR/Cas9 to the study of brain development and neuropsychiatric disease
Powell, S. K., Gregory, J. K., Akbarian, S., & Brennand, K. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.05.007 · Cited by 30
Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss?
Poluri, R. T. K., & Audet‐Walsh, É. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00246 · Cited by 28
Modeling and correction of structural variations in patient-derived iPSCs using CRISPR/Cas9
Park, C., Sung, J. J., Choi, S.-H., Lee, D. R., Park, I., & Kim, D. (2016) · Nature Protocols · doi:10.1038/nprot.2016.129 · Cited by 28
Genomic Engineering and the Future of Medicine
Doudna, J. A. (2015) · JAMA · doi:10.1001/jama.2015.287 · Cited by 27
CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy
Mintz, R. L., Gao, M. A., Lo, K., Lao, Y., Li, M., & Leong, K. W. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800132 · Cited by 27
Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
Torella, L., Klermund, J., Bilbao‐Arribas, M., Tamayo, I., Andrieux, G., Chmielewski, K. O., Vales, Á., Olagüe, C., Moreno, D., Raimondi, I., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-023-00008-8 · Cited by 27
Simultaneous paralogue knockout using a CRISPR-concatemer in mouse small intestinal organoids
Andersson-Rolf, A., Merenda, A., Mustata, R. C., Li, T., Dietmann, S., & Koo, B. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.10.016 · Cited by 27
Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine
Dai, X., Blancafort, P., Wang, P., Sgro, A., Thompson, E. W., & Ostrikov, K. (2020) · Advanced Science · doi:10.1002/advs.201902552 · Cited by 28
CRISPR Editing in Biological and Biomedical Investigation
Ju, X., Xu, J., & Sun, Z. S. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26154 · Cited by 27
Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering
Tang, K., Zhou, L., Tian, X., Fang, S., Vandenbulcke, E., Du, A., Shen, J., Cao, H., Zhou, J., Chen, K., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01371-2 · Cited by 27
Durability of Kinase-Directed Therapies—A Network Perspective on Response and Resistance
Murray, B. W., & Miller, N. L. G. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0088 · Cited by 27
Mladenova, V., Mladenov, E., & Iliakis, G. E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00163 · Cited by 28
Wu, T., Cao, Y., Liu, Q. L., Wu, X., Shang, Y., Piao, J., Li, Y., Dong, Y., Liu, D., Wang, H., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c01760 · Cited by 26
In Vivo Visualized Tracking of Tumor-Derived Extracellular Vesicles Using CRISPR-Cas9 System
Ye, Y., Shi, Q., Yang, T., Xie, F., Zhang, X., Xu, B., Fang, J., Chen, J., Zhang, Y., & Li, J. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221085370 · Cited by 26
Hunt, M. S., Yang, S. J., Mortensen, E., Boukhris, A., Buckner, J. H., Cook, P. J., & Rawlings, D. J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.016 · Cited by 27
Spraggon, L., Martelotto, L. G., Hmeljak, J., Hitchman, T. D., Wang, J., Wang, L., Slotkin, E. K., Fan, P., Reis-Filho, J. S., & Ladanyi, M. (2017) · The Journal of Pathology · doi:10.1002/path.4883 · Cited by 26
Rapid interrogation of cancer cell of origin through CRISPR editing
Feng, W., Cao, Z., Lim, P. X., Zhao, H., Luo, H., Mao, N., Lee, Y. S., Rivera, A. A., Choi, D., Wu, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110344118 · Cited by 25
Gene Editing in Non-Small Cell Lung Cancer: Current Application and Future Perspective
Wang, H., Fang, J., Wang, Y., Li, S., Wang, Z., He, W., Wang, N., Luo, S., Zou, H., & Zhang, F. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.021863 · Cited by 25
Kaneko, S., Takasawa, K., Asada, K., Shiraishi, K., Ikawa, N., Machino, H., Shinkai, N., Matsuda, M., Masuda, M., Adachi, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02035-6 · Cited by 26
Verschuren, E. H. J., Rigalli, J. P., Castenmiller, C., Rohrbach, M. U., Bindels, R. J. M., Peters, D. J. M., Arjona, F. J., & Hoenderop, J. G. J. (2020) · The FASEB Journal · doi:10.1096/fj.201902901r · Cited by 25
Bae, D. H., Marino, M., Iaffaldano, B. J., Fenstermaker, S., Afione, S. A., Argaw, T., McCright, J., Kwilas, A. R., Chiorini, J. A., Timmons, A. E., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.006 · Cited by 25
Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future
Mao, X., Dai, J., Zhou, H., Liu, Z., & Jin, W. (2016) · Oncotarget · doi:10.18632/oncotarget.8075 · Cited by 25
Efficient generation and reversion of chromosomal translocations using CRISPR/Cas technology
Lekomtsev, S., Aligianni, S., Lapão, A., & Bürckstümmer, T. (2016) · BMC Genomics · doi:10.1186/s12864-016-3084-5 · Cited by 26
Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion
Nikitski, A. V., Rominski, S. L., Wankhede, M., Kelly, L. M., Panebianco, F., Barila, G., Altschuler, D. L., & Nikiforov, Y. E. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.07.012 · Cited by 25
Boosting CAR-T cell therapy with CRISPR technology
Yan, L., Gao, S., Wang, X., Zhou, X., Limsakul, P., & Wu, Y. (2024) · hLife · doi:10.1016/j.hlife.2024.06.002 · Cited by 24
Walsh, R. M., Crabtree, G. W., Kalpana, K., Jubierre, L., Koo, S. Y., Ciceri, G., Gogos, J. A., Kruglikov, I., & Studer, L. (2025) · Neuron · doi:10.1016/j.neuron.2025.06.017 · Cited by 24
Liu, J., & Shui, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.014 · Cited by 24
CRISPR/Cas9-Mediated Genome Editing for Huntington’s Disease
Vachey, G., & Déglon, N. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7825-0_21 · Cited by 24
The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice
van der Weyden, L., Jonkers, J., & Adams, D. J. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.12.005 · Cited by 24
CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver
Kaltenbacher, T., Löprich, J., Maresch, R., Weber, J., Müller, S., Oellinger, R., Groß, N., Griger, J., Krätzig, N. D. A., Avramopoulos, P., et al. (2022) · Nature Protocols · doi:10.1038/s41596-021-00677-0 · Cited by 25
Langenau, D. M., Sweet-Cordero, A., Wechsler‐Reya, R. J., & Dyer, M. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1308 · Cited by 25
Therapeutic editing of hepatocyte genome in vivo
de Galarreta, M. R., & Lujambio, A. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.012 · Cited by 25
Metadata
- Authors
- Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., Lowe, S. W., & Ventura, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Azienda Ospedaliera San Gerardo (IT)
- Corresponding author
- Ventura, Andrea
- ORCID
- Venue
- Nature
- Published
- 2014-10-22
- Volume
- 516
- Issue
- 7531
- Pages
- 423-427
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4270925
- OpenAlex
- W1972759536
- Cited by
- 640
- References
- 30
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 43 · 2023: 45 · 2022: 61 · 2021: 53 · 2020: 53 · 2019: 55 · 2018: 68 · 2017: 65 · 2016: 81 · 2015: 63 · 2014: 2
- FWCI
- 28.86
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-06-24)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (P01CA129243, P01CA013106, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EML4-ALK fusion, chromosomal rearrangements, non-small cell lung cancer, somatic genome editing, tumor suppressor, oncogene cooperation
- MeSH terms
- Crizotinib, Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents, Cells, Cultured, Disease Models, Animal, Genetic Engineering, Chromosome Inversion, Lung Neoplasms, Pyrazoles, Pyridines, Translocation, Genetic, Receptor Protein-Tyrosine Kinases, NIH 3T3 Cells, Protein Kinase Inhibitors, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
